Hers vs Ro: Two Subscription-Telehealth GLP-1 Programs

A PlexusDx Education Hub comparison of two subscription-telehealth programs weight-loss shoppers frequently weigh against each other: Hers and Ro. Browse all Peptides & GLP-1 education

Independent editorial comparison. PlexusDx has no commercial relationship with Hers, Ro, or their parent companies, and no affiliate links or compensation are involved.

Hers and Ro sit closer together than many pairings — both are subscription telehealth brands that can prescribe GLP-1 medication — which makes the meaningful differences subtle and the shared pharmacology worth understanding. This is fair-balance education as of April 2026, focused on the two names in this query and the genetics neither addresses.

Comparing Hers and Ro on weight management

Both Hers and Ro are subscription-telehealth companies, so the comparison is less about model type and more about execution: provider structure, dispensing pathway, and how each packages its program. What they hold in common — virtual evaluation, provider-issued prescriptions, and a branded-or-compounded medication route — is the backdrop; the differences live in the details each publishes.

How Hers structures its program

Hers (Hims & Hers Health) operates as subscription telehealth: a virtual clinical evaluation, a provider-issued prescription, and either brand-name FDA-approved GLP-1 dispensing or compounded semaglutide and tirzepatide through licensed compounding-pharmacy pathways. Current program details are on Hers’s official website.

How Ro structures its program

Ro (Roman Health) also runs as subscription telehealth, with its own program structures, medication options, and pricing. Because those specifics shift over time, consult Ro’s official website for what applies on the day you read this.

The mechanism both programs rely on

Whichever brand you choose, both work in the GLP-1 receptor agonist space. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite regulation, satiety, and gastric emptying. The trial base — STEP (NEJM 2021), SURMOUNT (NEJM 2022), SURMOUNT-OSA (NEJM 2024) — belongs to the compound, not the platform. Effect sizes vary by compound, dose, and population.

Pricing you should verify at the source

Across the market as of April 2026, monthly totals span roughly $200 to $700+, folding in program fees, medication, and compounded dispensing where relevant. Hers and Ro each publish their own numbers; rather than trust a figure quoted secondhand, check each brand’s pricing page directly before any purchase decision.

The upstream genetics gap common to both

Neither Hers nor Ro reads the genetics behind a GLP-1 response. Variants in GLP1R, FTO, MC4R, and TCF7L2 map baseline receptor, appetite, and glucose biology. They are pathway-level — not predictive of response to a specific compound, but descriptive of the terrain any GLP-1 medication works on.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including GLP1R, FTO, MC4R, and TCF7L2 variants that shape your metabolic baseline. That is the test before you invest approach — context first, then an informed provider conversation.

Not affiliated: PlexusDx is not affiliated with Hers or Ro and holds no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Ro and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols; this comparison covers approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Weigh a third option: see the Weight Management Protocols, or begin with the Precision Peptide Genetic Test to read your GLP-1 pathway first.

Frequently Asked Questions

How do Hers and Ro differ in practice?

Both are subscription-telehealth brands, so the differences are in execution rather than model: provider structure, dispensing pathway, medication options, and how each packages and prices its program. Because those specifics change, compare each brand’s current published details side by side before choosing.

Do both Hers and Ro use compounded medication?

Both can route prescriptions to either FDA-approved branded GLP-1 products or compounded semaglutide and tirzepatide through licensed compounding pharmacies. Which pathway you receive depends on the program and product at the time. Confirm the specifics on each brand’s own site before enrolling.

Will the genetic test predict which program suits me?

No. The Precision Peptide Genetic Test does not predict response to Hers, Ro, or any specific compound. It analyzes pathway-level variants in GLP1R, FTO, MC4R, and TCF7L2 that describe baseline GLP-1 biology — upstream context that applies across every program regardless of brand.

What does PlexusDx offer that Hers and Ro don’t?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, paired with the Precision Peptide Genetic Test. The differentiator is pathway-level genetic insight mapping GLP1R, FTO, and MC4R variants — context that Hers, Ro, and most GLP-1 telehealth programs do not provide.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education